Niagen Bioscience, Inc. 8-K

What Happened

• On May 6, 2026 Niagen Bioscience, Inc. filed an 8-K (Items 2.02 and 7.01) to announce its earnings for the quarter ended March 31, 2026 and to disclose a corporate presentation the company made available on its website.
• The press release announcing the quarterly results is attached as Exhibit 99.1 and the earnings/corporate presentation is attached as Exhibit 99.2. The filing is signed by CFO Ozan Pamir.

Key Details

• Filing date: May 6, 2026 (8-K items 2.02: Results of Operations and Financial Condition; 7.01: Regulation FD Disclosure).
• Period covered: quarter ended March 31, 2026.
• Exhibits: 99.1 — Press Release dated May 6, 2026; 99.2 — Earnings/Corporate Presentation; 104 — Inline XBRL cover page.
• Authorized signature: Ozan Pamir, Chief Financial Officer (signed on behalf of the registrant).

Why It Matters

• The 8-K provides the company’s official, timely disclosure of its quarterly earnings and related presentation — key sources for investors seeking revenue, earnings, and management commentary for the quarter ended March 31, 2026.
• The Regulation FD disclosure and posted presentation ensure information was broadly distributed; investors should review the attached press release and presentation for the specific financial figures, trends, and any management discussion that could affect investment decisions.